PROGENICS PHARMACEUTICALS INC (PGNX) [Rocket]

Date Filed	Type	Description
06/16/2020	GN	Progenics Stockholders Approve Merger with Lantheus
04/23/2020	GN	Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7
03/13/2020	GN	PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
01/16/2020	GN	Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting
12/22/2019	GN	Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd
12/12/2019	GN	SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers
12/10/2019	GN	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNX
12/04/2019	GN	INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX
11/25/2019	GN	Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting
11/21/2019	GN	Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer
11/08/2019	GN	Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections
11/04/2019	GN	Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan's Nominees Control of the Board
11/01/2019	GN	Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan's Consent Solicitation